Genotype-restricted lymphoproliferation in autoimmune lpr mice

Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus

Systemic lupus erythematosus is characterized by the production of autoantibodies directed against nuclear Ags, including nucleosome and DNA. TLR9 is thought to play a role in the production of these autoantibodies through the capacity of nuclear immunogenic particles to interact both with BCR and TLR9. To determine the role of TLR9 in SLE, C57BL/6-lpr/lpr-TLR9(-/-) and TLR9(+/+) mice were analyzed. The abrogation of TLR9 totally impaired the production of anti-nucleosome Abs, whereas no difference was observed in the frequency of anti-dsDNA autoantibodies whose titer was strikingly higher in TLR9(-/-) mice. In addition a higher rate of mesangial proliferation was observed in the kidney of TLR9-deficient animals. These results indicate that in C57BL/6-lpr/lpr mice, TLR9 is absolutely required for the anti-nucleosome Ab response but not for anti-dsDNA Ab production which is involved in mesangial proliferation.

Significant role of Fas ligand-binding but defective Fas receptor (CD95) in lymph node hyperplasia composed of abnormal double-negative T cells

The functional differences between two mutations of the Fas (CD95) locus, Faslpr (lpr) and Faslprcg (lprcg), were investigated using bone marrow (BM) transplantation on the C3H mouse background. Both lpr/lpr and lprcg/lprcg BM transferred caused lymph node (LN) hyperplasia in lpr/+ and lprcg/+ recipients, although it was clearly smaller than that in lpr/lpr and lprcg/lprcg recipients of lpr/lpr and lprcg/lprcg BM. In addition, both BM induced significantly larger LN hyperplasia in lprcg/+ than lpr/+ recipients. Appearance of CD4- CD8-[double negative (DN)] T cells in the periphery is the most consistent phenotype of Fas mutations. Importantly, the proportion of DN T cells was higher in larger LN hyperplasia in the order of lpr/+, lprcg/+ and lpr/lpr or lprcg/lprcg recipients. On the other hand, both lpr/lpr and lprcg/lprcg BM transferred into wild-type (+/+) mice caused marked LN atrophy. The former, but not the latter, induced wasting syndrome. Faslg1d (gld)-homozygous lpr/lpr BM transferred into +/+ mice elicited LN hyperplasia of the same extent as that in lpr/lpr mice transferred with lpr/lpr BM, but not wasting syndrome. Taken together with the fact that DN T cells massively express Fas ligand (FasL), this study implied that FasL overexpressed on DN cells may be involved in the accumulation of DN T cells in LN, LN atrophy and wasting syndrome, and that lprcg Fas, which can bind to Fas ligand but not transduce apoptosis signal into cells, may modulate these pathological conditions by interfering with the binding of FasL to Fas.

The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations

Heterozygous mutations of the receptor CD95 (Fas/Apo-1) are associated with defective lymphocyte apoptosis and a clinical disease characterized by lymphadenopathy, splenomegaly, and systemic autoimmunity. From our cohort of 11 families, we studied eight patients to define the mechanisms responsible for defective CD95-mediated apoptosis. Mutations in and around the death domain of CD95 had a dominant-negative effect that was explained by interference with the recruitment of the signal adapter protein, FADD, to the death domain. The intracellular domain (ICD) mutations were associated with a highly penetrant Canale-Smith syndrome (CSS) phenotype and an autosomal dominant inheritance pattern. In contrast, mutations affecting the CD95 extracellular domain (ECD) resulted in failure of extracellular expression of the mutant protein or impaired binding to CD95 ligand. They did not have a dominant-negative effect. In each of the families with an ECD mutation, only a single individual was affected. These observations were consistent with differing mechanisms of action and modes of inheritance of ICD and ECD mutations, suggesting that individuals with an ECD mutation may require additional defect(s) for expression of CSS.

A role for FADD in T cell activation and development

FADD is a cytoplasmic adapter molecule that links the family of death receptors to the activation of caspases during apoptosis. We have produced transgenic mice expressing a dominantly interfering mutant of FADD, lacking the caspase-dimerizing death effector domain, as well as mice overexpressing the poxvirus serpin, CrmA, an inhibitor of caspases downstream of FADD. While thymocytes from either line of mice were completely protected from CD95-dependent cytotoxicity, neither transgene afforded protection from apoptosis induced during thymocyte selection and neither led to the lymphoproliferative disorders associated with deficiencies in CD95. However, in FADD dominant negative (FADDdd) mice, early thymocyte development was retarded and peripheral lymphocyte pools were devoid of normal populations of T cells. We show that thymocytes and peripheral T cells from FADDdd display signaling anomalies, implying that FADD plays a previously uncharacterized role in T cell development and activation.

Lymphadenopathy induced by the cooperation between lprcg and gld genes is of lpr but not of gld phenotype

Mice homozygous for the lpr (lymphoproliferation), lprcg or gld (generalized lymphoproliferative disease) mutation develop strikingly similar lymphadenopathy with expansion of B220+ CD4- CD8- double-negative (DN) T cells and autoimmunity. To elucidate the roles of bone marrow (BM) and lymph node (LN) in lymphoproliferation, BM and LN were transplanted simultaneously into normal or +/+ mice in various genotype combinations. In lpr/lpr or lprcg/lprcg BM recipients grafted lpr/lpr and lprcg/lprcg LN swelled but +/+ and gld/gld LN atrophied. In gld/gld BM recipients all of LN swelled regardless of genotype. Thus, lpr and lprcg are phenotypically different from gld in the interaction of BM-derived DN T cells and +/+ LN. Compared with lpr the lprcg gene differs in its ability to complement with gld in induction of lymphadenopathy. To determine whether lymphoproliferation induced by the cooperation between lprcg and gld is of lpr or gld phenotype, LN of various genotypes were implanted into double heterozygous lprcg/+, gld/+ mice. Grafted lpr/lpr and lprcg/lprcg LN swelled but +/+ and gld/gld LN atrophied, indicating that it is of lpr phenotype. Moreover, grafted lprcg/+ LN swelled but lpr/+ LN atrophied, indicating that, in the heterozygous state, lprcg is phenotypically different from lpr as it allows for LN accumulation of DN T cells induced by lprcg-gld cooperation.

Autoimmunity in mice bearing lprcg: a novel mutant gene

A novel mutation at the lpr (lymphoproliferation)(Fas) locus, lprcg, that can complement gld (generalized lymphoproliferative disease) in induction of lymphadenopathy was discovered in CBA/K1Jms mice. The lpr and lprcg mutations are a defective allele of the Fas locus that encodes an apoptosis-mediating receptor. The former does not express the receptor and the latter expresses the point-mutated nonfunctional receptor. The gld locus is hypothesized to encode a ligand for the receptor and the gld mutation to have a defect that leads to incompetent expression of the ligand. The absence and non-functioning of the receptor in lpr/lpr and lprcg/lprcg mice, respectively, and the lack of the ligand in gld/gld mice may arrest apoptosis of lymphoid cells in the thymus, resulting in the same type of lymphadenopathy characterized by expansion of unusual CD4-CD8- (DN) T cells. Less severe lymphadenopathy induced by complementarity between lprcg and gld may be explained by less efficient apoptosis resulting from competition for the ligand between the functional and nonfunctional receptors. Phenotypically, lpr and lprcg are different from gld in the function at bone marrow (BM) and lymph node (LN) levels: lpr/lpr and lprcg/lprcg BM cause atrophy but gld/gld BM hyperplasia of wild-type (+/+) LNs, and lpr/lpr and lprcg/lprcg LNs but not gld/gld LNs allow the homing of lpr- and lprcg-induced DN T cells. Lymphadenopathy is equally prominent in CBA-lprcg/lprcg and MRL-lprcg/lprcg mice. Hypergammaglobulinemia, autoantibodies and circulating immune complexes are detectable at significant levels in both lprcg/lprcg mice but at higher levels on the MRL background. Pathological signs like glomerulonephritis and vasculitis are clinically unimportant in CBA-lprcg/lprcg but strikingly severe in MRL-lprcg/lprcg mice. Noticeably, clinically significant glomerulonephritis and vasculitis also develop with slight but significant serological aberrations in MRL-lprcg/+ heterozygotes. Graft-vs.-host disease-like syndrome in the lprcg/lprcg BM-->+/+ chimera is minimal on the CBA but as severe as life-threatening on the MRL background as in the MRL-lpr/lpr BM-->MRL(-)+/+ chimera. Thus, autoimmune diseases induced by the lpr, lprcg and gld genes are actually indistinguishable in the clinical, serological and pathological aspects on the same strain background and the disease caused by the interaction between lprcg and gld is less severe in all the aspects, consistent with the receptor-ligand theory. The lprcg/lprcg mice with different strain backgrounds together with lpr/lpr and gld/gld mice will serve as a powerful tool for elucidation of the mechanism of development of single-gene autoimmune diseases at a molecular biological level.

B-cell tolerance

Discrimination between self and non-self in humoral immunity is mediated in part by elimination or inactivation of self-reactive B-cell clones. This type of repertoire censoring requires that self-reactive B cells make a choice between these and alternative cellular fates. The details of this developmental decision-making and the steps where it is prone to go awry in autoimmunity have yet to be untangled, but genetic analysis appears likely to lead the way.